CytomX Therapeutics (NASDAQ:CTMX) Earns Neutral Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a research report released on Thursday morning, Benzinga reports.

A number of other research analysts have also weighed in on CTMX. StockNews.com lowered CytomX Therapeutics from a buy rating to a hold rating in a research report on Monday, June 17th. Jefferies Financial Group raised CytomX Therapeutics from a hold rating to a buy rating and upped their price objective for the stock from $2.50 to $8.00 in a report on Monday, May 6th. JPMorgan Chase & Co. raised shares of CytomX Therapeutics from an underweight rating to a neutral rating in a report on Monday, April 22nd. BMO Capital Markets upped their price target on shares of CytomX Therapeutics from $3.25 to $3.59 and gave the company a market perform rating in a research note on Thursday, May 9th. Finally, Wedbush raised shares of CytomX Therapeutics from a neutral rating to an outperform rating and lifted their price objective for the stock from $3.00 to $8.00 in a research note on Thursday, May 9th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of Hold and a consensus target price of $5.77.

CytomX Therapeutics Stock Performance

Shares of CytomX Therapeutics stock opened at $1.22 on Thursday. The company has a fifty day moving average of $1.97 and a 200 day moving average of $1.87. The company has a market capitalization of $95.06 million, a P/E ratio of 6.10 and a beta of 1.14. CytomX Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.23. CytomX Therapeutics had a net margin of 13.87% and a negative return on equity of 30.70%. The business had revenue of $41.46 million during the quarter, compared to analyst estimates of $23.40 million. Analysts forecast that CytomX Therapeutics will post -0.14 EPS for the current year.

Institutional Investors Weigh In On CytomX Therapeutics

Several institutional investors have recently made changes to their positions in the company. AlphaMark Advisors LLC raised its position in CytomX Therapeutics by 119.8% in the 4th quarter. AlphaMark Advisors LLC now owns 23,183 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 12,635 shares during the period. SG Americas Securities LLC purchased a new position in CytomX Therapeutics in the 1st quarter worth about $57,000. Susquehanna Fundamental Investments LLC purchased a new stake in CytomX Therapeutics in the 1st quarter valued at about $124,000. Congress Park Capital LLC grew its stake in CytomX Therapeutics by 112.8% in the 4th quarter. Congress Park Capital LLC now owns 239,300 shares of the biotechnology company’s stock worth $371,000 after acquiring an additional 126,850 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in shares of CytomX Therapeutics by 1.7% during the first quarter. Acadian Asset Management LLC now owns 2,690,830 shares of the biotechnology company’s stock worth $5,863,000 after acquiring an additional 44,640 shares during the period. Institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.